The scientific basis and future of lipoprotein apheresis
File(s)
Author(s)
Thompson, Gilbert R
Type
Journal Article
Abstract
Lipoprotein apheresis plays a vital role in the management of the severe hyperlipidemias that predispose to atherosclerosis. Determinants of efficacy are the acute reduction in lipoproteins achieved by each apheresis procedure, their frequency, and the fractional catabolic rates and hence pool sizes of low-density lipoprotein (LDL) or lipoprotein (a) (Lp(a)) of the patient being treated. A useful criterion of the efficacy of apheresis plus lipid-lowering drug therapy is the decrease in the interval (time-averaged) mean of serum total or LDL cholesterol or Lp(a) between procedures, expressed as the percent decrease in the interval means below the maximal levels of these lipoproteins when off all treatment. Recent advances in lipid-lowering drug therapy may diminish the use of lipoprotein apheresis but will not abolish its unique role as a therapeutic "last chance saloon," especially for children and pregnant women with homozygous familial hypercholesterolemia.
Date Issued
2022-02-01
Date Acceptance
2021-07-26
Citation
Therapeutic Apheresis and Dialysis, 2022, 26 (1), pp.32-36
ISSN
1744-9979
Publisher
Wiley
Start Page
32
End Page
36
Journal / Book Title
Therapeutic Apheresis and Dialysis
Volume
26
Issue
1
Copyright Statement
© 2021 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy. This is the accepted version of the following article: Thompson, GR. The scientific basis and future of lipoprotein apheresis. Ther Apher Dial. 2021; 1– 5, which has been published in final form at https://doi.org/10.1111/1744-9987.13716
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/34331508
Subjects
atherosclerosis
cholesterol
familial hypercholesterolemia
Publication Status
Published
Coverage Spatial
Australia
Date Publish Online
2021-07-31